BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioCardia, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -120.3% | -139.3% | -950.1% | |
| Return on assets | -76.5% | -96.5% | -230.6% | |
| Current ratio | 15.18 | 5.33 | 1.12 | |
| Interest coverage | -4.4× | -5176.3× | – | |
| Inventory turnover | 1.7× | – | – | |
| Capex to revenue | – | 22.1% | – | |
| Diluted shares | 1M | 10M | 7M |
Where the cash went
Fiscal 2021 to 2025, five years combined
BioCardia generated $46.22M from operations and spent $211.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$46.22M
Used
$211.00K
Capital expenditure$211.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-13700.0%
×Asset turnover0.02×
×Equity multiplier-8.76×
=Return on equity, FY20242074.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -13700.0% | 0.02× | -8.76× | 2074.7% |
| FY2023 | -2425.8% | 0.07× | 3.89× | -703.6% |
| FY2022 | -880.7% | 0.11× | 1.67× | -156.0% |
| FY2021 | -1243.6% | 0.05× | 1.32× | -85.4% |
| FY2020 | -10347.6% | 0.01× | 1.44× | -139.3% |
| FY2019 | -2071.7% | 0.10× | 2.29× | -477.4% |
| FY2018 | -2237.9% | 0.06× | 1.34× | -187.5% |
| FY2017 | -2569.5% | 0.03× | 1.12× | -77.6% |
| FY2016 | -1789.9% | 0.04× | 1.57× | -120.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.23M
- Cash generatingOperating cash flow above zero-$7.44M
- Return on assets improvedROA up on the prior year-266.0% → -220.9%
- Earnings backed by cashOperating cash flow above net income-$7.44M vs -$8.23M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.13 → 1.12
- No dilutionShare count did not rise3M → 7M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.00